DK1037615T3 - Præparater og fremgangsmåder til behandling af attention deficit desorder og attention deficit/hyperactivity disorder med methylphenidat - Google Patents

Præparater og fremgangsmåder til behandling af attention deficit desorder og attention deficit/hyperactivity disorder med methylphenidat

Info

Publication number
DK1037615T3
DK1037615T3 DK98963170T DK98963170T DK1037615T3 DK 1037615 T3 DK1037615 T3 DK 1037615T3 DK 98963170 T DK98963170 T DK 98963170T DK 98963170 T DK98963170 T DK 98963170T DK 1037615 T3 DK1037615 T3 DK 1037615T3
Authority
DK
Denmark
Prior art keywords
attention deficit
disorder
methylphenidate
preparations
treatment
Prior art date
Application number
DK98963170T
Other languages
Danish (da)
English (en)
Inventor
Juan Mantelle
Terese A Dixon
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1037615(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Application granted granted Critical
Publication of DK1037615T3 publication Critical patent/DK1037615T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DK98963170T 1997-12-15 1998-12-14 Præparater og fremgangsmåder til behandling af attention deficit desorder og attention deficit/hyperactivity disorder med methylphenidat DK1037615T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
DK1037615T3 true DK1037615T3 (da) 2004-07-12

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98963170T DK1037615T3 (da) 1997-12-15 1998-12-14 Præparater og fremgangsmåder til behandling af attention deficit desorder og attention deficit/hyperactivity disorder med methylphenidat

Country Status (28)

Country Link
US (2) US6210705B1 (fr)
EP (2) EP1037615B1 (fr)
JP (3) JP4316800B2 (fr)
KR (1) KR100633348B1 (fr)
CN (1) CN1368876A (fr)
AR (1) AR014062A1 (fr)
AT (1) ATE260652T1 (fr)
AU (1) AU752027B2 (fr)
BR (1) BR9814282A (fr)
CA (1) CA2315237C (fr)
CZ (2) CZ300535B6 (fr)
DE (1) DE69822199T2 (fr)
DK (1) DK1037615T3 (fr)
ES (2) ES2452517T3 (fr)
HK (1) HK1049447A1 (fr)
HU (1) HU226615B1 (fr)
IL (1) IL136760A0 (fr)
LV (1) LV12558B (fr)
NO (1) NO329974B1 (fr)
NZ (1) NZ505689A (fr)
PE (1) PE20000120A1 (fr)
PL (1) PL195315B1 (fr)
PT (1) PT1037615E (fr)
RU (1) RU2233156C2 (fr)
SI (1) SI20360B (fr)
TR (1) TR200001736T2 (fr)
TW (2) TWI244396B (fr)
WO (1) WO1999030694A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
AU2199901A (en) * 1999-12-17 2001-06-25 Medeva Europe Limited The treatment of convulsive states
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CN1250206C (zh) * 2001-03-07 2006-04-12 久光制药株式会社 贴剂
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
UA84303C2 (ru) * 2003-10-28 2008-10-10 Новен Фармасьютикалз, Инк. Система для трансдермальной доставки лечебного средства
AU2006206410B2 (en) * 2005-01-20 2012-08-30 Ampio Pharmaceuticals, Inc. Methylphenidate derivatives and uses of them
SI1845780T1 (sl) * 2005-01-20 2012-01-31 Inst Molecular Medicine Inc Uporaba derivatov metilfenidata
WO2007077029A1 (fr) * 2005-12-23 2007-07-12 Epinamics Gmbh Utilisation de polymeres filmogenes de soins capillaires a partir du groupe des polyurethanes et preparations pharmaceutiques et pansements adhesifs contenant ces polymeres
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
CN101431988A (zh) * 2006-02-27 2009-05-13 诺芬药品公司 包含东莨菪碱的透皮治疗系统
AU2007248284B2 (en) * 2006-05-01 2011-03-17 Colgate-Palmolive Company Oral care composition with silicone composite
CA2678806C (fr) * 2007-02-21 2017-05-16 Connected Health Systems, Llc Traitement du tdah et d'autres maladies impliquant une inflammation
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
WO2009075782A1 (fr) 2007-12-06 2009-06-18 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
JP2011507665A (ja) * 2007-12-31 2011-03-10 アクラレント インコーポレイテッド 粘膜組織包帯剤及び使用方法
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
WO2009146320A1 (fr) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Procédés et composés thérapeutiques
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
ES2651175T3 (es) * 2009-06-05 2018-01-24 Babcock & Wilcox Megtec, Llc Barra flotante de infrarrojos mejorada
EP2364695A1 (fr) 2010-02-10 2011-09-14 Nitto Denko Corporation Préparation de timbre au méthylphénidiate
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
CA3123900A1 (en) 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
CA2891467A1 (fr) 2012-10-15 2014-04-24 Noven Pharmaceuticals, Inc. Compositions et procedes pour l'administration transdermique de methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
MX366230B (es) 2012-12-28 2019-07-03 Noven Pharma Composiciones multipolimericas para liberación transdermica de farmaco.
JP2016505006A (ja) 2012-12-28 2016-02-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド レボノルゲストレル及びエチニルエストラジオール用の経皮薬物送達システム
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11337936B2 (en) 2013-03-14 2022-05-24 Noven Pharmaceuticals, Inc. Amphetamine transdermal compositions with acrylic block copolymer
CA2905131A1 (fr) 2013-03-15 2014-09-18 Durect Corporation Compositions ayant un agent de modification rheologique pour reduire une variabilite de dissolution
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
JP6518397B2 (ja) 2013-12-25 2019-05-22 株式会社フジモト・コーポレーション 注意欠如・多動性障害の予防および治療剤
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
WO2018107132A1 (fr) 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprenant des promédicaments méthylphénidates, procédés de fabrication et d'utilisation de ces compositions
EP3598982A1 (fr) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugués de dérivés de neuropeptides
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
WO1992021333A2 (fr) * 1991-05-24 1992-12-10 Pharmavene, Inc. Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
KR950702436A (ko) 1992-07-28 1995-07-29 자코부스 코르넬리스 라세르 가교 결합 양이온성 중합체 및 알콜실화 에테르를 함유하는 국소용 약학 조성물(pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether)
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
DE59507025D1 (de) 1994-06-29 1999-11-18 Hennecke Gmbh Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Schaumstoffblöcken oder Schaumstoffbahnen
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1998039042A1 (fr) 1997-03-07 1998-09-11 Jackson Richard R Matiere plastique pour materiel d'anesthesie ou d'administration de medicaments, produits, systemes et procedes medicaux associes
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
WO2001044720A1 (fr) 1999-12-15 2001-06-21 Osaka Gas Co., Ltd. Distributeur de fluide, dispositif a bruleur, moteur de turbine a gaz, et systeme cogenerateur

Also Published As

Publication number Publication date
EP1037615B1 (fr) 2004-03-03
NZ505689A (en) 2003-01-31
KR20010033114A (ko) 2001-04-25
US6348211B1 (en) 2002-02-19
CZ2009132A3 (cs) 2016-03-23
JP2002510600A (ja) 2002-04-09
WO1999030694A2 (fr) 1999-06-24
WO1999030694A3 (fr) 1999-08-19
RU2233156C2 (ru) 2004-07-27
HK1049447A1 (zh) 2003-05-16
ES2219926T3 (es) 2004-12-01
PL341596A1 (en) 2001-04-23
CN1368876A (zh) 2002-09-11
KR100633348B1 (ko) 2006-10-16
PE20000120A1 (es) 2000-02-19
LV12558B (en) 2001-03-20
DE69822199T2 (de) 2005-02-17
HUP0004539A3 (en) 2006-06-28
JP2009073856A (ja) 2009-04-09
TW200406231A (en) 2004-05-01
DE69822199D1 (de) 2004-04-08
NO20003096L (no) 2000-08-15
CA2315237A1 (fr) 1999-06-24
TWI244396B (en) 2005-12-01
HK1156872A1 (en) 2012-06-22
EP2314288A1 (fr) 2011-04-27
EP1037615A2 (fr) 2000-09-27
TR200001736T2 (tr) 2001-01-22
EP2314288B1 (fr) 2013-12-11
CA2315237C (fr) 2009-12-01
IL136760A0 (en) 2001-06-14
TWI242452B (en) 2005-11-01
NO20003096D0 (no) 2000-06-15
SI20360A (sl) 2001-04-30
HU226615B1 (en) 2009-04-28
BR9814282A (pt) 2000-10-03
ATE260652T1 (de) 2004-03-15
NO329974B1 (no) 2011-01-31
PT1037615E (pt) 2004-07-30
CZ20002209A3 (cs) 2000-11-15
AU752027B2 (en) 2002-09-05
HUP0004539A2 (hu) 2001-06-28
AR014062A1 (es) 2001-01-31
CZ305817B6 (cs) 2016-03-23
JP2013056944A (ja) 2013-03-28
CZ300535B6 (cs) 2009-06-10
JP4316800B2 (ja) 2009-08-19
LV12558A (lv) 2000-11-20
ES2452517T3 (es) 2014-04-01
US6210705B1 (en) 2001-04-03
AU1824999A (en) 1999-07-05
SI20360B (sl) 2008-06-30
PL195315B1 (pl) 2007-08-31

Similar Documents

Publication Publication Date Title
HUP0004539A3 (en) Composition and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
DK1011621T3 (da) Fremgangsmåder og præparater til hvidning af tænder
DK0811006T3 (da) Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
IS2321B (is) Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum
DK0781136T3 (da) Forbindelser og fremgangsmåder til behandling af cancer
EP0958364A4 (fr) Immunotherapie et vaccins perfectionnes
DK0486290T3 (da) Fremgangsmåde og præparat til forøgelse af akkumulering af squalen og specifikke steroler i gær
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO983576L (no) Br°nnbehandlingsfluider og fremgangsmÕter
DK0592139T3 (da) Middel til primerbehandling og rensning på basis af organosilan
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
DK0961609T3 (da) Fremgangsmåde til forbedring af sundhedstilstanden af hår og hovedbund
DK0792323T3 (da) Funktionaliserede polyorganosiloxaner og en af fremgangsmåderne til deres fremstilling
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK1140824T3 (da) Fremgangsmåde til fremstilling af 3-alkanoyl- og 3-alkylindoler
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0917464T3 (da) Anvendelse af aminer til fremstilling af lægemidler til forebyggelse af tumorcelleproliferation
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK0876573T3 (da) Keramisk tænder og fremgangsmåde til anvendelse af samme
DK21795A (da) Fremgangsmåde til fremstilling og oprensning af ioderede kontrastmidler
DK1017388T3 (da) Farmaceutiske præparater indeholdende ibuprofen og domperidon til behandling af migræne
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
DK1021200T3 (da) Fremgangsmåder og præparater til behandling af rheumatoid arthritis
IS4957A (is) Hreinsuð prótein, samskeyttar DNA raðir og aðferðir til að stýra þroskun kaffiplantna